Todd W Costantini1, Raul Coimbra, Jessica L Weaver, Brian P Eliceiri. 1. From the Department of Surgery (T.W.C., J.L.W., B.P.E.), Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, UC San Diego School of Medicine, San Diego; and Comparative Effectiveness and Clinical Outcomes Research Center (R.C.), Riverside University Health System, Loma Linda University School of Medicine, Riverside, California.
Abstract
BACKGROUND: The systemic inflammatory response (SIRS) drives late morbidity and mortality after injury. The α7 nicotinic acetylcholine receptor (α7nAchR) expressed on immune cells regulates the vagal anti-inflammatory pathway that prevents an overwhelming SIRS response to injury. Nonspecific pharmacologic stimulation of the vagus nerve has been evaluated as a potential therapeutic to limit SIRS. Unfortunately, the results of clinical trials have been underwhelming. We hypothesized that directly targeting the α7nAchR would more precisely stimulate the vagal anti-inflammatory pathway on immune cells and decrease gut and lung injury after severe burn. METHODS: C57BL/6 mice underwent 30% total body surface area steam burn. Mice were treated with an intraperitoneal injection of a selective agonist of the α7nAchR (AR-R17779) at 30 minutes postburn. Intestinal permeability to 4 kDa FITC-dextran was measured at multiple time points postinjury. Lung vascular permeability was measured 6 hours after burn injury. Serial behavioral assessments were performed to quantify activity levels. RESULTS: Intestinal permeability peaked at 6 hours postburn. AR-R17779 decreased burn-induced intestinal permeability in a dose-dependent fashion (p < 0.001). There was no difference in gut permeability to 4 kDa FITC-dextran between sham and burn-injured animals treated with 5 mg/kg of AR-R17779. While burn injury increased lung permeability 10-fold, AR-R17779 prevented burn-induced lung permeability with no difference compared with sham (p < 0.01). Postinjury activity levels were significantly improved in burned animals treated with AR-R17779. CONCLUSION: Directly stimulating the α7nAchR prevents burn-induced gut and lung injury. Directly targeting the α7nAChR that mediates the cholinergic anti-inflammatory response may be an improved strategy compared with nonspecific vagal agonists.
BACKGROUND: The systemic inflammatory response (SIRS) drives late morbidity and mortality after injury. The α7 nicotinic acetylcholine receptor (α7nAchR) expressed on immune cells regulates the vagal anti-inflammatory pathway that prevents an overwhelming SIRS response to injury. Nonspecific pharmacologic stimulation of the vagus nerve has been evaluated as a potential therapeutic to limit SIRS. Unfortunately, the results of clinical trials have been underwhelming. We hypothesized that directly targeting the α7nAchR would more precisely stimulate the vagal anti-inflammatory pathway on immune cells and decrease gut and lung injury after severe burn. METHODS: C57BL/6 mice underwent 30% total body surface area steam burn. Mice were treated with an intraperitoneal injection of a selective agonist of the α7nAchR (AR-R17779) at 30 minutes postburn. Intestinal permeability to 4 kDa FITC-dextran was measured at multiple time points postinjury. Lung vascular permeability was measured 6 hours after burn injury. Serial behavioral assessments were performed to quantify activity levels. RESULTS: Intestinal permeability peaked at 6 hours postburn. AR-R17779 decreased burn-induced intestinal permeability in a dose-dependent fashion (p < 0.001). There was no difference in gut permeability to 4 kDa FITC-dextran between sham and burn-injured animals treated with 5 mg/kg of AR-R17779. While burn injury increased lung permeability 10-fold, AR-R17779 prevented burn-induced lung permeability with no difference compared with sham (p < 0.01). Postinjury activity levels were significantly improved in burned animals treated with AR-R17779. CONCLUSION: Directly stimulating the α7nAchR prevents burn-induced gut and lung injury. Directly targeting the α7nAChR that mediates the cholinergic anti-inflammatory response may be an improved strategy compared with nonspecific vagal agonists.
Authors: Michael Krzyzaniak; Carrie Peterson; William Loomis; Ann-Marie Hageny; Paul Wolf; Luiz Reys; James Putnam; Brian Eliceiri; Andrew Baird; Vishal Bansal; Raul Coimbra Journal: J Trauma Date: 2011-05
Authors: Iris Dotan; Daniel Rachmilewitz; Stefan Schreiber; Rami Eliakim; C Janneke van der Woude; Asher Kornbluth; Alan L Buchman; Shimon Bar-Meir; Bernd Bokemeyer; Eran Goldin; Christian Maaser; Uma Mahadevan; Ursula Seidler; Jörg C Hoffman; Douglas Homoky; Terry Plasse; Barbara Powers; Paul Rutgeerts; Daniel Hommes Journal: Gut Date: 2010-06 Impact factor: 23.059
Authors: Frieda A Koopman; Sangeeta S Chavan; Sanda Miljko; Simeon Grazio; Sekib Sokolovic; P Richard Schuurman; Ashesh D Mehta; Yaakov A Levine; Michael Faltys; Ralph Zitnik; Kevin J Tracey; Paul P Tak Journal: Proc Natl Acad Sci U S A Date: 2016-07-05 Impact factor: 11.205
Authors: Maria E Hammarlund; Vladimer Darsalia; Filip Mjörnstedt; Bagmi Pattanaik; Carina Mallard; Eridan Rocha-Ferreira; Cesare Patrone; Maria E Johansson Journal: Biosci Rep Date: 2021-06-25 Impact factor: 3.840
Authors: Christopher J Czura; Marom Bikson; Leigh Charvet; Jiande D Z Chen; Manfred Franke; Marat Fudim; Eric Grigsby; Sam Hamner; Jared M Huston; Navid Khodaparast; Elliot Krames; Bruce J Simon; Peter Staats; Kristl Vonck Journal: Front Neurol Date: 2022-07-14 Impact factor: 4.086